707 related articles for article (PubMed ID: 36949949)
61. Engineering strategies for broad application of TCR-T- and CAR-T-cell therapies.
Watanabe K; Nishikawa H
Int Immunol; 2021 Oct; 33(11):551-562. PubMed ID: 34374779
[TBL] [Abstract][Full Text] [Related]
62. Prospects and challenges for use of CAR T cell therapies in solid tumors.
Ramakrishna S; Barsan V; Mackall C
Expert Opin Biol Ther; 2020 May; 20(5):503-516. PubMed ID: 32125191
[No Abstract] [Full Text] [Related]
63. Targeting cancers through TCR-peptide/MHC interactions.
He Q; Jiang X; Zhou X; Weng J
J Hematol Oncol; 2019 Dec; 12(1):139. PubMed ID: 31852498
[TBL] [Abstract][Full Text] [Related]
64. Surmounting the obstacles that impede effective CAR T cell trafficking to solid tumors.
Donnadieu E; Dupré L; Pinho LG; Cotta-de-Almeida V
J Leukoc Biol; 2020 Oct; 108(4):1067-1079. PubMed ID: 32620049
[TBL] [Abstract][Full Text] [Related]
65. Off-the-Shelf Allogeneic T Cell Therapies for Cancer: Opportunities and Challenges Using Naturally Occurring "Universal" Donor T Cells.
Perez C; Gruber I; Arber C
Front Immunol; 2020; 11():583716. PubMed ID: 33262761
[TBL] [Abstract][Full Text] [Related]
66. Current Headway in Cancer Immunotherapy Emphasizing the Practice of Genetically Engineered T Cells to Target Selected Tumor Antigens.
Ray SK; Mukherjee S
Crit Rev Immunol; 2021; 41(1):23-40. PubMed ID: 33822523
[TBL] [Abstract][Full Text] [Related]
67. A TCR-based Chimeric Antigen Receptor.
Walseng E; Köksal H; Sektioglu IM; Fåne A; Skorstad G; Kvalheim G; Gaudernack G; Inderberg EM; Wälchli S
Sci Rep; 2017 Sep; 7(1):10713. PubMed ID: 28878363
[TBL] [Abstract][Full Text] [Related]
68. Proceedings From the First International Workshop at Sidra Medicine: "Engineered Immune Cells in Cancer Immunotherapy (EICCI): From Discovery to Off-the-Shelf Development", 15
Guerrouahen B; Elnaggar M; Al-Mohannadi A; Kizhakayil D; Bonini C; Benjamin R; Brentjens R; Buchholz CJ; Casorati G; Ferrone S; Locke FL; Martin F; Schambach A; Turtle C; Veys P; van der Vliet HJ; Maccalli C;
Front Immunol; 2020; 11():589381. PubMed ID: 33584653
[TBL] [Abstract][Full Text] [Related]
69. CAR T Cell Therapy for Solid Tumors.
Newick K; O'Brien S; Moon E; Albelda SM
Annu Rev Med; 2017 Jan; 68():139-152. PubMed ID: 27860544
[TBL] [Abstract][Full Text] [Related]
70. Chimeric Antigen Receptor T Cell Based Immunotherapy for Cancer.
Li F; Zhang T; Cao L; Zhang Y
Curr Stem Cell Res Ther; 2018; 13(5):327-335. PubMed ID: 29676233
[TBL] [Abstract][Full Text] [Related]
71. T-cell receptor and chimeric antigen receptor in solid cancers: current landscape, preclinical data and insight into future developments.
Azizi AA; Pillai M; Thistlethwaite FC
Curr Opin Oncol; 2019 Sep; 31(5):430-438. PubMed ID: 31335828
[TBL] [Abstract][Full Text] [Related]
72. Enhancing CAR T-cell therapies against solid tumors: Mechanisms and reversion of resistance.
Qin Y; Xu G
Front Immunol; 2022; 13():1053120. PubMed ID: 36569859
[TBL] [Abstract][Full Text] [Related]
73. Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects.
Di S; Li Z
Sci China Life Sci; 2016 Apr; 59(4):360-9. PubMed ID: 26968709
[TBL] [Abstract][Full Text] [Related]
74. Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure.
Wachsmann TLA; Wouters AK; Remst DFG; Hagedoorn RS; Meeuwsen MH; van Diest E; Leusen J; Kuball J; Falkenburg JHF; Heemskerk MHM
Oncoimmunology; 2022; 11(1):2033528. PubMed ID: 35127255
[TBL] [Abstract][Full Text] [Related]
75. Establishment and validation of in-house cryopreserved CAR/TCR-T cell flow cytometry quality control.
Cai Y; Prochazkova M; Jiang C; Song HW; Jin J; Moses L; Gkitsas N; Somerville RP; Highfill SL; Panch S; Stroncek DF; Jin P
J Transl Med; 2021 Dec; 19(1):523. PubMed ID: 34952597
[TBL] [Abstract][Full Text] [Related]
76. Next-generation CAR T cells to overcome current drawbacks.
Lundh S; Maji S; Melenhorst JJ
Int J Hematol; 2021 Nov; 114(5):532-543. PubMed ID: 32594314
[TBL] [Abstract][Full Text] [Related]
77. New Strategies for the Treatment of Solid Tumors with CAR-T Cells.
Zhang H; Ye ZL; Yuan ZG; Luo ZQ; Jin HJ; Qian QJ
Int J Biol Sci; 2016; 12(6):718-29. PubMed ID: 27194949
[TBL] [Abstract][Full Text] [Related]
78. Adoptive cell therapy in paediatric extracranial solid tumours: current approaches and future challenges.
Zappa E; Vitali A; Anders K; Molenaar JJ; Wienke J; Künkele A
Eur J Cancer; 2023 Nov; 194():113347. PubMed ID: 37832507
[TBL] [Abstract][Full Text] [Related]
79. [Adoptive therapy with TCR gene-modified T cells for hematological malignancies and solid tumors].
Ikeda H
Rinsho Ketsueki; 2019; 60(6):716-722. PubMed ID: 31281165
[TBL] [Abstract][Full Text] [Related]
80. Revolution of CAR Engineering For Next-Generation Immunotherapy In Solid Tumors.
Yu T; Yu SK; Xiang Y; Lu KH; Sun M
Front Immunol; 2022; 13():936496. PubMed ID: 35903099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
